公开(公告)号：EP2390270A1

公开(公告)日：2011-11-30

申请号：EP11162977.0

申请日：2004-01-09

申请人： Ablynx N.V.

发明人： Silence, Karen

IPC分类号： C07K16/36 ,  C07K16/18 ,  C12N15/13 ,  A61K39/395 ,  A61K38/49 ,  A61P7/02 ,  A61M31/00 ,  C07K16/28

CPC分类号： C07K16/18 ,  A61K38/166 ,  A61K38/49 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61L29/085 ,  A61L29/16 ,  A61L31/10 ,  A61L31/16 ,  A61L2300/256 ,  A61L2300/42 ,  A61L2420/02 ,  C07K16/2896 ,  C07K16/36 ,  C07K2317/22 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/569 ,  G01N33/68 ,  G01N33/6893 ,  G01N33/86 ,  G01N2333/47 ,  G01N2333/755 ,  G01N2500/02 ,  G01N2500/04 ,  G01N2800/222 ,  A61K2300/00

摘要： The present invention relates to polypeptides comprising at least one single domain antibody directed against vWF, vWF A1 domain, A1 domain of activated vWF, vWF A3 domain, gplb and/or collagen, homologues of said polypeptides, and/or functional portions of said polypeptides, for the treatment for conditions which require a modulation of platelet-mediated aggregation and which overcomes the problems of the prior art. A further aspect of the invention is methods of production of said polypeptides, methods to coat devices with such polypeptides used in medical procedures (e.g. PCTA, stenting), methods and kits for screening for agents that modulate platelet-mediated aggregation and kits for the diagnosis of diseases related to platelet-mediated aggregation.

摘要翻译： 本发明涉及包含针对vWF，vWF A1结构域，活化的vWF的A1结构域，vWF A3结构域，gpb和/或胶原，所述多肽的同系物和/或所述多肽的功能部分的至少一个单结构域抗体的多肽 ，用于治疗需要调节血小板介导的聚集并克服现有技术的问题的条件。 本发明的另一方面是生产所述多肽的方法，用于医疗程序中使用的这种多肽（例如PCTA，支架置入）的装置的方法，用于筛选调节血小板介导的聚集的试剂和用于诊断的试剂盒的方法和试剂盒 与血小板介导的聚集相关的疾病。

公开(公告)号：EP2265948A4

公开(公告)日：2011-04-20

申请号：EP09717826

申请日：2009-02-26

申请人： BIOMEDOMICS INC

发明人： WANG XUE-FENG

IPC分类号： G01N33/53 ,  G01N33/543

CPC分类号： G01N33/86 ,  G01N2333/522 ,  G01N2400/40 ,  G01N2800/222 ,  Y10S435/97

公开(公告)号：EP2265948A2

公开(公告)日：2010-12-29

申请号：EP09717826.3

申请日：2009-02-26

申请人： Biomedomics, Inc.

发明人： WANG, Xue-Feng

IPC分类号： G01N33/53

CPC分类号： G01N33/86 ,  G01N2333/522 ,  G01N2400/40 ,  G01N2800/222 ,  Y10S435/97

摘要： Disclosed herein is a lateral flow immuno-assay system capable of rapidly, cost effectively, and quantitatively detecting and assessing the level of HIT antibodies in body fluids of a patient. Also taught are methods for employing the system to assist in diagnosis of HIT, and for screening or detecting a changing titer of HIT antibodies in the body fluids of a patient to determine susceptibility toward HIT.

公开(公告)号：EP1957532A4

公开(公告)日：2009-11-11

申请号：EP06839971

申请日：2006-11-20

申请人： UNIV OREGON HEALTH & SCIENCE

发明人： BAKKE ANTONY

IPC分类号： C07K16/00 ,  C07K14/47 ,  G01N33/564

CPC分类号： G01N33/542 ,  G01N33/564 ,  G01N2800/222

公开(公告)号：EP1987057A2

公开(公告)日：2008-11-05

申请号：EP07703325.6

申请日：2007-02-07

申请人： Stiftung für Diagnostische Forschung

发明人： RIGAL, Dominique ,  THIBAUT, Julien ,  GILLET, Gemain ,  MERIEUX, Yves

IPC分类号： C07K7/08 ,  G01N33/564 ,  C07K19/00 ,  A61K38/10 ,  A61K38/16

CPC分类号： G01N33/564 ,  C07K7/08 ,  C07K2319/00 ,  G01N2333/745 ,  G01N2500/02 ,  G01N2800/222

摘要： The present invention relates to a peptide aptamer which mimics particularly the human platelet antigene HPA-Ia epitope present on the platelet GPIIb/llla molecules and which is capable of neutralizing the binding of HPA-I a specific antibodies (anti-HPA-1 a). This peptide aptamer is advantageously used in a method for detecting and identifying HPA-I a specific antibodies in human serum, in a diagnostic kit for screening and identifying antibodies, in an immunoassay and a pharmaceutical composition.

公开(公告)号：EP1942186A2

公开(公告)日：2008-07-09

申请号：EP08004264.1

申请日：2000-04-25

申请人： Sanofi-Aventis Deutschland GmbH

发明人： Clementson, Kenneth J.

IPC分类号： C12N15/12 ,  C07K14/705 ,  A61K38/17 ,  G01N33/68

CPC分类号： C07K14/745 ,  A61K38/00 ,  C07K14/70503 ,  C07K14/755 ,  C07K16/28 ,  C07K16/2803 ,  C07K2317/20 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/76 ,  G01N33/86 ,  G01N2015/0084 ,  G01N2333/4728 ,  G01N2333/78 ,  G01N2500/02 ,  G01N2800/222

摘要： The invention relates to Glycoprotein VI (GPVI), its isolation, purification, and methods for recombinant production. Especially, the invention relates to the use of GPVI, preferably recombinant GPVI, in the treatment of disorders and pathological events correlated directly or indirectly to blood coagulation disorders such as thrombotic and cardiovascular diseases.The extracellular recombinant protein can also be used for establishing screening assays to find potential inhibitors of the membrane bound GPVI in order to inhibit binding of thrombocytes and platelets, respectively, to collagen.

公开(公告)号：EP1890155A1

公开(公告)日：2008-02-20

申请号：EP06119102.9

申请日：2006-08-17

申请人： F. Hoffmann-La Roche AG ,  Roche Diagnostics GmbH

发明人： Spanuth, Eberhard ,  Ivandic, Boris

IPC分类号： G01N33/86 ,  A61B5/15

CPC分类号： G01N33/86 ,  G01N2015/0084 ,  G01N2800/222

摘要： The invention provides a method for diagnosing platelet (thrombocyte) function comprising the steps of (a) obtaining a blood platelet-containing sample from a subject, and (b) preferably keeping the sample under conditions capable of inhibiting plasmatic coagulation and/or fibrin formation, (c) bringing a marker of platelet function derived from the platelets, or a variant of such marker into solution, wherein at least steps b) and c) are carried out in a blood sampling device and/or wherein additionally the level of the marker of platelet function in the solution is measured. Preferably, the marker of platelet function is brought into solution by activating the platelets in vitro or by means of proteolysis. Preferred markers of platelet function include CD40L, sCD40L, P-selectin, soluble P-selectin, GP-IV, soluble GP-IV, GP-V, soluble GP-V, GP-VI, soluble GP-VI, CD63, platelet factor-4 (PF-4), β-Thromboglobulin (β-TG), or variants thereof. The method provides for diagnosis or determining of platelet hypo- or hyperfunction, cardiovascular disorders and any disorders associated with platelet hypo- or hyperfunction.

摘要翻译： 本发明提供的方法用于诊断血小板（凝血细胞）的功能，包括（a）从受试者获得一个含有血小板的血液试样的步骤，和（b）优选保持能够抑制血浆凝血和/或纤维蛋白形成的条件下将样品 （C）使从血小板，或搜索标记进入溶液的变体衍生的血小板功能的标志物，在b以上步骤worin）和c）在一个血液采样装置被执行和/或worin的另外的水平 在溶液中的血小板功能的标志物被测量。 优选地，血小板功能的标记是由在体外活化或通过蛋白水解的手段血小板制成溶液。 血小板功能的优选的标记物包括CD40L，sCD40L的，P-选择，可溶性P-选择，GP-IV，可溶性GP-IV，GP-V，可溶性GP-V，GP-VI，可溶性GP-VI，CD63，血小板因子 -4（PF-4）²血小板球蛋白（²-TG），或其变体。 该方法提供了诊断或血小板低渗或超支功能，心血管障碍的确定性采矿和与血小板低渗或超功能相关的任何病症。

公开(公告)号：EP1810031A2

公开(公告)日：2007-07-25

申请号：EP05810321.9

申请日：2005-10-04

申请人： Akers Biosciences, Inc.

发明人： MILUNIC, David ,  ANDRELCZYK, Susan

IPC分类号： G01N33/543

CPC分类号： G01N33/6863 ,  B01L3/5023 ,  B01L2200/16 ,  B01L2300/0681 ,  B01L2400/0683 ,  G01N33/54313 ,  G01N33/564 ,  G01N33/6893 ,  G01N33/86 ,  G01N2333/522 ,  G01N2400/40 ,  G01N2800/222

摘要： Methods for determining the presence of heparin/platelet factor 4 antibodies in a sample suspected to contain heparin/platelet factor 4 antibodies are provided, along with apparatus suitable for performing the methods. The method depends upon a color visualization indicating the presence or absence of heparin/platelet factor 4 antibodies in the sample. Preferred methods comprise contacting the sample with particles being complexed to platelet factor 4 (PF4) and which particle-complexed PF4 reacts specifically with heparin/platelet factor 4 antibodies, passing the sample/particle mixture through a filter, and then analyzing the color of the filtrate. The presence of heparin/platelet factor 4 antibodies in the sample is established where the color of the filtrate is substantially different from the color of the receptor-bearing particles.

公开(公告)号：EP1743031A2

公开(公告)日：2007-01-17

申请号：EP05756157.3

申请日：2005-04-26

申请人： CHILDREN'S MEDICAL CENTER CORPORATION

发明人： FOLKMAN, Judah ,  KLEMENT, Giannoula

IPC分类号： C12Q1/00

CPC分类号： G01N33/6893 ,  G01N33/574 ,  G01N33/57488 ,  G01N33/86 ,  G01N2333/515 ,  G01N2800/222 ,  G01N2800/52

摘要： The present inventors have surprisingly discovered that platelets sequester angiogenic regulators and prevent their degradation. Thus, by analyzing levels of angiogenic regulators in platelets, it is now possible to detect angiogenic activity, even at an early stage. By monitoring for changes in angiogenic activity, the presence of cancer or other angiogenic diseases or disorders can be predicted.

公开(公告)号：EP1597383A2

公开(公告)日：2005-11-23

申请号：EP04710148.0

申请日：2004-02-11

申请人： Pacific Edge Biotechnology Limited

发明人： MORISON, Ian M.

IPC分类号： C12Q1/00 ,  C12Q1/68 ,  C07K1/00 ,  C07K14/00 ,  C07H21/02

CPC分类号： C12Q1/6883 ,  C07K14/80 ,  C12Q2600/156 ,  G01N33/6893 ,  G01N2333/80 ,  G01N2800/222

摘要： Embodiments of this invention include oligonucleotides associated with one or mutations associated with familial thrombocytopenia and methods suitable for their detection. Embodiements of this invention include isolated peptides and/or proteins comprising a serine residue at position 42 of the HCS protein. This invention also includes antibodies directed at nucleic acids, peptides or proteins comprising at least a portion of HCS having a serine reside at positon 42. Other embodiements include devices, kits and methods for detecting markers associated with familial thrombocytopenia associated with the HCS42g-s mutation, or to therapies for HCS42g-s using antisense oligonucleotides.